Chinese government cafeterias go non-GMO; public schoolchildren still being fed poisons Outrage erupted in medical world following China’s Ministry of Education recently announced that it does not serve genetically altered organisms to diners at its cafeteria generique-et-marque-levitra.htm . GMWatch.org and others report that the federal government agency has a sign currently posted in the doorway of its cafeteria stating that GMOs aren’t served to government employees or users of the public who might go to the facility, yet these same transgenic derivatives continue to be served to China’s open public schoolchildren. The indication, which clearly claims that the protection profile of GMOs is usually questionable at greatest, was made to dispel fears about the inadvertent consumption of unlabeled GMOs in the cafeteria. Without verifiable or genuine consensus on whether GMOs are secure for the environment, aside from human consumption, the government agency has chosen to take the precautionary approach by eliminating them entirely in the best interests of federal government employees and others who dine at the canteen. ‘The problem of whether GM food is harmful to human health is currently without consensus within academia,’ reads an English translation of the sign, that you can view right here. ‘To get rid of the issues of diners, also to assure the safety and health of our workers, our Ministry of Education Office Canteen temporarily won’t use food oil containing GM elements and GM food components. Please enjoy your meal without the such concern.’ Ministry of Education says GMOs are too risky for government employees but safe for schoolchildren This position would be laudable if it applied across the table to every institution in China. But according to reports, general public schoolchildren in China are becoming subjected to GMOs on a regular basis still, in large part due to attempts by China’s Ministry of Agriculture to thwart the task of parents and other people who want to preserve the quality and integrity of cafeteria meals served to China’s most vulnerable segment of society. ‘They remain serving GM food in college cafeterias in China,’ writes Nancy Swanson for Examiner.com about the presssing issue. ‘Bans on GM meals in school cafeterias had been blocked by the Chinese [Ministry] of Agriculture, which does not serve GM food in [its] personal kindergarten. And now the Chinese Ministry of Education proudly proclaims that they don’t serve GM food in their office canteen in order that we can enjoy consuming there without concern.’ Ministry of Finance also bars GMOs, despite their continued use in education Comparable sentiments concerning the long-term protection of GMOs are sensed by China’s Ministry of Financing as well. The agency recently declared a GMO-free policy of its own, bringing to light the sponsor of food safety issues that currently plagues China and the need to avoid causing any more by secretly slipping untested transgenic additives into the food supply. ‘[T]he basis of a country is the people,’ stated Ministry of Finance minister associate Liu Hong-wei throughout a recent series of particular meetings on strengthening food and drug basic safety in China. ‘[P]eople treat meals like heaven, with security as top priority,’ he added, noting that ‘the fitness of workers is more essential than anything, [and] the need for food safety posesses heavier weight than the Taishan mountain.’ This same policy should, of program, connect with everyone in China, including small children and members of everyone. But apparently a similar standard of corruption exists in China as it does in the U.S., where corporate influence trumps public opinion, resulting in lies, double standards and, regarding GMOs, widespread environmental pollution and human illness.
3 billion population. China will invest 850 billion RMB on healthcare from 2009 to 2011, further stimulating demand for medical products, in what is already among the world’s fastest developing marketplaces for medical technology. One year later, a true number of new rules and guidelines are in place, which are starting to reshape the framework of the Chinese healthcare industry. Whilst the national government hasn’t released details of how the purchase will be distributed, InMedica believes that around 50 percent will be utilized to expand the insurance coverage of medical insurance, 30 percent will be utilized for the structure of rural health care systems, and the remaining 20 percent will be used to invest in public hospitals. It is the very first time that basic healthcare will be offered as a open public service for all people in China, and the Chinese federal government aims to resolve the problems that have caused strong complaints from the general public about high medical costs. The overall aim is to supply basic medical services to the populace by 2011, with the long-term objective of rolling out universal coverage by 2020. The healthcare reform relies on joint funding by local and central governments. The central federal government will contribute around 40 percent of the total 850 billion RMB expenditure. Pubic, non-revenue hospitals shall stay the major provider of healthcare services, but even more priority will be given to the development of grassroots-level clinics and hospitals. The central authorities will fund the construction of 2,000 county-level hospitals, 29,000 township hospitals and the upgrading of 5,000 township hospitals. Furthermore, about 3,700 community health centers and 11,000 community health stations shall be established or upgraded by 2011. Because the reform was announced last April, a number of regulations and suggestions have already been released. In June 2009, the guideline on the construction of county hospitals, health centres, community health services centres, and village treatment centers was released; in 2009 October, the guideline on the price of essential drugs premiered; and in January 2010, a guideline on teaching and development of village physicians premiered. Most recently, in 2010 February, the guideline on the reform of public hospitals in 16 pilot cities was released. Public medical center reform was among the key issues of the guideline. Currently, public hospital revenues derive from drug product sales, medical services and authorities funds. In 2007, the full total revenues of public hospitals in China was 375.4 billion RMB, including 200 billion RMB from the sales of medicines. In the same year, funds from the government had been 28.5 billion RMB, that was only 7.6 percent of total revenues. Currently, public hospitals are permitted to create a 15 percent profit from drug sales. Whilst this market-oriented strategy has improved medical providers recently greatly, it has also led to soaring medical charges for the Chinese public. Related StoriesApplying a high restaurant model to healthcare communications: an interview with Brandi Robinson, SanofiCancer medical diagnosis improvements in England: an interview with Lucy Elliss-BrookesReducing medical center readmissions through Transitional Treatment: an interview with Rani KhetarpalAccording to the guideline, the 15 percent profit from drug sales won’t be permitted. However, it is thought that government financing alone can not fully meet the financial gap, in the Western regions especially. Relating to Owen Tang, marketplace analyst at InMedica, ‘with limited government funding obtainable, it really is unknown if the general public hospitals can maintain criteria of treatment without the revenues from drug sales. For this reason the federal government has chosen 16 metropolitan areas to pilot the reform. The cities, including six in central China, six in the east and four in the west, were asked to start out the reform out of this full year. The government will require time to evaluate the success of the early trials, and possibly conduct more trials with refined recommendations, prior to the healthcare reform could be rolled-out on a nationwide level. Regardless of the impressive headline expenditure figures, China’s health care reform may very well be an extended process.’ InMedica predicts that the main winners in the medical gadgets market will become suppliers of basic equipment, such as for example general purpose ultrasound devices, analogue X-ray tools and patient monitors, which are funded by the healthcare reform. Chinese businesses such as Mindray, Beijing Yuyue and Wandong Medical will advantage the most, as regional suppliers are favored by the government because of the ‘Buy China’ initiative. These topics and even more are discussed in a new statement from InMedica called ‘Evaluation of the Chinese Health care Industry: A Guide for Medical Device Manufacturers’. If you want an interview with a specialist in this area, please contact Simon Harris, Study Director, at or +44 1933 402255. About InMedica InMedica may be the medical analysis division of IMS Research ( an expert supplier of market consultancy and research services on an array of global electronics markets. The ongoing organization is backed by headquarters in Wellingborough, Offices and UK in Austin, Shanghai and Texas, China. InMedica regularly publishes detailed study on professional stage of care markets such as ultrasound and x-ray tools, and consumer medical products such as for example blood-pressure monitors and heart-rate monitors.